Investigating how a specific protein variant affects cancer and DNA damage

Mdm2 Alternative Splicing in DNA Damage and Cancer

NIH-funded research Research Inst Nationwide Children's Hosp · NIH-10911135

This study is looking at a special version of a protein called MDM2 that helps control another important protein, p53, which fights cancer; researchers want to understand how this version behaves under stress and how it might be used to create better treatments for cancer.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionResearch Inst Nationwide Children's Hosp NIH-funded
Lab location1 site (Columbus, United States)
Project IDNIH-10911135 on NIH RePORTER

What this research studies

This research focuses on understanding the role of an alternative form of the MDM2 protein in regulating the p53 tumor suppressor pathway, which is crucial for preventing cancer. The study examines how this protein variant, MDM2-ALT1, is produced in response to cell stress and its dual role in promoting or inhibiting cancer progression. By using advanced techniques, researchers aim to identify the mechanisms behind MDM2-ALT1 expression and explore the potential of targeting this variant with specific therapies to improve cancer treatment outcomes.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals diagnosed with specific types of cancers such as pediatric high-grade gliomas, astrocytomas, and certain adult cancers like lymphomas and breast cancer.

Not a fit: Patients with cancers not associated with MDM2-ALT1 expression or those without a diagnosis of cancer may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the effectiveness of cancer treatments by targeting the MDM2-ALT1 protein.

How similar studies have performed: Previous research has shown promising results in targeting alternative splicing in cancer, suggesting that this approach may lead to significant advancements in treatment.

Where this research is happening

Columbus, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.